ARS Pharmaceuticals, Inc.
SPRY
$5.24
-$0.15-2.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -62.34M | -60.62M | -41.32M | -51.15M | -44.88M |
| Total Depreciation and Amortization | 416.00K | 397.00K | 417.00K | 391.00K | 279.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.83M | 6.68M | 4.89M | 4.78M | 6.16M |
| Change in Net Operating Assets | -12.84M | 8.60M | -7.46M | -1.07M | -1.15M |
| Cash from Operations | -60.93M | -44.95M | -43.49M | -47.05M | -39.59M |
| Capital Expenditure | -- | -- | 0.00 | -197.00K | -51.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 41.57M | 27.79M | 24.11M | -44.78M | 48.62M |
| Cash from Investing | 41.57M | 27.79M | 24.11M | -44.98M | 48.57M |
| Total Debt Issued | -- | -- | -1.49M | 97.75M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 786.00K | 62.00K | 1.78M | 479.00K | 2.70M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.41M | 97.00K | 844.00K | 1.82M | -- |
| Cash from Financing | 3.20M | 159.00K | 1.13M | 100.05M | 2.70M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.16M | -17.00M | -18.24M | 8.02M | 11.68M |